Share：
Share this content in WeChat
X
[Chinese][PDF]2612
• Review •
Research progress of 4D Flow MRI in hypertrophic cardiomyopathy
ZHANG Lina  FENG Yan  XIONG Shengyuan  MA Mingzhong  ZHOU Xing 

Cite this article as: ZHANG L N, FENG Y, XIONG S Y, et al. Research progress of 4D Flow MRI in hypertrophic cardiomyopathy[J]. Chin J Magn Reson Imaging, 2023, 14(12): 177-180, 186. DOI:10.12015/issn.1674-8034.2023.12.032.


[Abstract] 4D Flow MRI is an in vivo non-invasive quantitative blood flow imaging technique that has been rapidly developed in recent years. It is used in hemodynamic studies of cardiac large vessels, head and neck, and peripheral blood vessels. Hypertrophic cardiomyopathy (HCM) is a common primary and hereditary heart disease in clinic. This article mainly introduces the imaging principle of 4D Flow MRI and its application in HCM. The relevant literature is intended to summarize the characteristics of hemodynamic parameters of HCM obtained by 4D Flow MRI technology, and provide imaging evidence for early intervention and treatment of HCM patients.
[Keywords] magnetic resonance imaging；four-dimensional flow magnetic resonance imaging；hypertrophic cardiomyopathy；left ventricular outflow tract obstruction；mitral regurgitation；turbulent kinetic energy

ZHANG Lina1   FENG Yan1   XIONG Shengyuan2   MA Mingzhong2   ZHOU Xing2*  

1 First School of Clinical Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China

2 Radiology Department, Gansu Provincial People's Hospital, Lanzhou 730000, China

Corresponding author: ZHOU X, E-mail: xingzhoulzu@163.com

Conflicts of interest   None.

Received  2023-05-29
Accepted  2023-11-29
DOI: 10.12015/issn.1674-8034.2023.12.032
Cite this article as: ZHANG L N, FENG Y, XIONG S Y, et al. Research progress of 4D Flow MRI in hypertrophic cardiomyopathy[J]. Chin J Magn Reson Imaging, 2023, 14(12): 177-180, 186. DOI:10.12015/issn.1674-8034.2023.12.032.

[1]
MARON B J, DESAI M Y, NISHIMURA R A, et al. Diagnosis and evaluation of HypertrophicCardiomyopathy: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2022, 79(4): 372-389. DOI: 10.1016/j.jacc.2021.12.002.
[2]
CHOWDHARY A, GARG P, DAS A, et al. Cardiovascular magnetic resonance imaging: emerging techniques and applications[J]. Heart, 2021, 107(9): 697-704. DOI: 10.1136/heartjnl-2019-315669.
[3]
MATTHIA E L, SETTEDUCATO M L, ELZENEINI M, et al. Circulating biomarkers in hypertrophic cardiomyopathy[J/OL]. J Am Heart Assoc, 2022, 11(23): e027618 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/36382968/. DOI: 10.1161/JAHA.122.027618.
[4]
Cardiomyopathy Junior Coalition National Center for Cardiovascular Disease, Chinese Health Care Heart Vascular Disease Precision Medical Branch for the Promotion of International Exchange "Chinese adult hypertrophic cardiomyopathy diagnosis and treatment guidelines" Panel. 2023 guideline for diagnosis and treatment of patients with hypertrophic cardiomyopathy[J]. Chin Circ J, 2023, 38(1): 1-33. DOI: 10.3969/j.issn.1000-3614.2023.01.001.
[5]
MURESAN I D, AGOSTON-COLDEA L. Phenotypes of hypertrophic cardiomyopathy: genetics, clinics, and modular imaging[J]. Heart Fail Rev, 2021, 26(5): 1023-1036. DOI: 10.1007/s10741-020-09931-1.
[6]
MARIAN A J. Molecular genetic basis of hypertrophic cardiomyopathy[J]. Circ Res, 2021, 128(10): 1533-1553. DOI: 10.1161/CIRCRESAHA.121.318346.
[7]
PRUIJSSEN J T, ALLEN B D, BARKER A J, et al. Hypertrophic cardiomyopathy is associated with altered left ventricular 3D blood flow dynamics[J/OL]. Radiol Cardiothorac Imaging, 2020, 2(1): e190038 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/33778534/. DOI: 10.1148/ryct.2020190038.
[8]
SOULAT G, MCCARTHY P, MARKL M. 4D flow with MRI[J/OL]. Annu Rev Biomed Eng, 2020, 22: 103-126 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/32155346/. DOI: 10.1146/annurev-bioeng-100219-110055.
[9]
CERNE J W, PATHROSE A, GORDON D Z, et al. Evaluation of pulmonary hypertension using 4D flow MRI[J]. J Magn Reson Imaging, 2022, 56(1): 234-245. DOI: 10.1002/jmri.27967.
[10]
RIZK J. 4D flow MRI applications in congenital heart disease[J]. Eur Radiol, 2021, 31(2): 1160-1174. DOI: 10.1007/s00330-020-07210-z.
[11]
AZARINE A, GARÇON P, STANSAL A, et al. Four-dimensional flow MRI: principles and cardiovascular applications[J]. Radiographics, 2019, 39(3): 632-648. DOI: 10.1148/rg.2019180091.
[12]
CHERRY M, KHATIR Z, KHAN A, et al. The impact of 4D-Flow MRI spatial resolution on patient-specific CFD simulations of the thoracic aorta[J/OL]. Sci Rep, 2022, 12(1): 15128 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/36068322/. DOI: 10.1038/s41598-022-19347-6.
[13]
CORRADO P A, WENTLAND A L, STAREKOVA J, et al. Fully automated intracardiac 4D flow MRI post-processing using deep learning for biventricular segmentation[J]. Eur Radiol, 2022, 32(8): 5669-5678. DOI: 10.1007/s00330-022-08616-7.
[14]
BLANKEN C P S, GOTTWALD L M, WESTENBERG J J M, et al. Whole-heart 4D flow MRI for evaluation of normal and regurgitant valvular flow: a quantitative comparison between pseudo-spiral sampling and EPI readout[J]. J Magn Reson Imaging, 2022, 55(4): 1120-1130. DOI: 10.1002/jmri.27905.
[15]
DAI Z H, IGUCHI N, TAKAMISAWA I, et al. Alcohol septal ablation markedly reduces energy loss in hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: a four-dimensional flow cardiac magnetic resonance study[J/OL]. Int J Cardiol Heart Vasc, 2021, 37: 100886 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/34692989/. DOI: 10.1016/j.ijcha.2021.100886.
[16]
ALLEN B D, CHOUDHURY L, BARKER A J, et al. Three-dimensional haemodynamics in patients with obstructive and non-obstructive hypertrophic cardiomyopathy assessed by cardiac magnetic resonance[J]. Eur Heart J Cardiovasc Imaging, 2015, 16(1): 29-36. DOI: 10.1093/ehjci/jeu146.
[17]
HA H, KIM G B, KWEON J, et al. Hemodynamic measurement using four-dimensional phase-contrast MRI: quantification of hemodynamic parameters and clinical applications[J]. Korean J Radiol, 2016, 17(4): 445-462. DOI: 10.3348/kjr.2016.17.4.445.
[18]
BISSELL M M, RAIMONDI F, AIT ALI L, et al. 4D Flow cardiovascular magnetic resonance consensus statement: 2023 update[J/OL]. J Cardiovasc Magn Reson, 2023, 25: 40 [2023-05-28]. https://jcmr-online.biomedcentral.com/articles/10.1186/s12968-023-00942-z. DOI: 10.1186/s12968-023-00942-z.
[19]
BURRIS N S, HOPE M D. 4D flow MRI applications for aortic disease[J]. Magn Reson Imaging Clin N Am, 2015, 23(1): 15-23. DOI: 10.1016/j.mric.2014.08.006.
[20]
DEMIRKIRAN A, VAN OOIJ P, WESTENBERG J J M, et al. Clinical intra-cardiac 4D flow CMR: acquisition, analysis, and clinical applications[J]. Eur Heart J Cardiovasc Imaging, 2022, 23(2): 154-165. DOI: 10.1093/ehjci/jeab112.
[21]
ITATANI K, SEKINE T, YAMAGISHI M, et al. Hemodynamic parameters for cardiovascular system in 4D flow MRI: mathematical definition and clinical applications[J]. Magn Reson Med Sci, 2022, 21(2): 380-399. DOI: 10.2463/mrms.rev.2021-0097.
[22]
WARMERDAM E, KRINGS G J, LEINER T, et al. Three-dimensional and four-dimensional flow assessment in congenital heart disease[J]. Heart, 2020, 106(6): 421-426. DOI: 10.1136/heartjnl-2019-315797.
[23]
ZHUANG B Y, SIRAJUDDIN A, ZHAO S H, et al. The role of 4D flow MRI for clinical applications in cardiovascular disease: current status and future perspectives[J]. Quant Imaging Med Surg, 2021, 11(9): 4193-4210. DOI: 10.21037/qims-20-1234.
[24]
MARKL M, KILNER P J, EBBERS T. Comprehensive 4D velocity mapping of the heart and great vessels by cardiovascular magnetic resonance[J/OL]. J Cardiovasc Magn Reson, 2011, 13(1): 7 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/21235751/. DOI: 10.1186/1532-429X-13-7.
[25]
DOYLE C M, ORR J, GREENWOOD J P, et al. Four-dimensional flow magnetic resonance imaging in the assessment of blood flow in the heart and great vessels: a systematic review[J]. J Magn Reson Imaging, 2022, 55(5): 1301-1321. DOI: 10.1002/jmri.27874.
[26]
NAKAZA M, MATSUMOTO M, SEKINE T, et al. Dual-VENC 4D flow MRI can detect abnormal blood flow in the left atrium that potentially causes thrombosis formation after left upper lobectomy[J]. Magn Reson Med Sci, 2022, 21(3): 433-443. DOI: 10.2463/mrms.mp.2020-0170.
[27]
MARKL M, |FRYDRYCHOWICZ A, KOZERKE S, et al. 4D flow MRI[J]. J Magn Reson Imag JMRI, 2012, 36(5): 1015-1036. DOI: 10.1002/jmri.23632.
[28]
KROEGER J R, STACKL M, WEISS K, et al. K-t accelerated multi-VENC 4D flow MRI improves vortex assessment in pulmonary hypertension[J/OL]. Eur J Radiol, 2021, 145: 110035 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/34801875/. DOI: 10.1016/j.ejrad.2021.110035.
[29]
XU Q L, YE Y B, ZHANG J K, et al. Research advances in clinical application of 4D Flow MRI[J]. Chin J Med Imag Technol, 2017, 33(12): 1898-1901. DOI: 10.13929/j.1003-3289.201706118.
[30]
PEREIRA V M, DELATTRE B, BRINA O, et al. 4D flow MRI in neuroradiology: techniques and applications[J]. Top Magn Reson Imaging, 2016, 25(2): 81-87. DOI: 10.1097/RMR.0000000000000082.
[31]
GUPTA A N, SOULAT G, AVERY R, et al. 4D flow MRI left atrial kinetic energy in hypertrophic cardiomyopathy is associated with mitral regurgitation and left ventricular outflow tract obstruction[J]. Int J Cardiovasc Imaging, 2021, 37(9): 2755-2765. DOI: 10.1007/s10554-021-02167-6.
[32]
GUPTA A N, AVERY R, SOULAT G, et al. Direct mitral regurgitation quantification in hypertrophic cardiomyopathy using 4D flow CMR jet tracking: evaluation in comparison to conventional CMR[J/OL]. J Cardiovasc Magn Reson, 2021, 23(1): 138 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/34865629/. DOI: 10.1186/s12968-021-00828-y.
[33]
OECHTERING T H, NOWAK A, SIEREN M M, et al. Repeatability and reproducibility of various 4D Flow MRI postprocessing software programs in a multi-software and multi-vendor cross-over comparison study[J/OL]. J Cardiovasc Magn Reson, 2023, 25(1): 22 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/36978131/. DOI: 10.1186/s12968-023-00921-4.
[34]
MARON M S, OLIVOTTO I, ZENOVICH A G, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction[J]. Circulation, 2006, 114(21): 2232-2239. DOI: 10.1161/CIRCULATIONAHA.106.644682.
[35]
IAVARONE M, MONDA E, VRITZ O, et al. Medical treatment of patients with hypertrophic cardiomyopathy: an overview of current and emerging therapy[J]. Arch Cardiovasc Dis, 2022, 115(10): 529-537. DOI: 10.1016/j.acvd.2022.06.003.
[36]
CIBIS M, BUSTAMANTE M, ERIKSSON J, et al. Creating hemodynamic atlases of cardiac 4D flow MRI[J]. J Magn Reson Imaging, 2017, 46(5): 1389-1399. DOI: 10.1002/jmri.25691.
[37]
GORECKA M, BISSELL M M, HIGGINS D M, et al. Rationale and clinical applications of 4D flow cardiovascular magnetic resonance in assessment of valvular heart disease: a comprehensive review[J/OL]. J Cardiovasc Magn Reson, 2022, 24(1): 49 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/35989320/. DOI: 10.1186/s12968-022-00882-0.
[38]
DIRIX P, BUOSO S, PEPER E S, et al. Synthesis of patient-specific multipoint 4D flow MRI data of turbulent aortic flow downstream of stenotic valves[J/OL]. Sci Rep, 2022, 12(1): 16004 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/36163357/. DOI: 10.1038/s41598-022-20121-x.
[39]
IWATA K, SEKINE T, MATSUDA J, et al. Measurement of turbulent kinetic energy in hypertrophic cardiomyopathy using triple-velocity encoding 4D flow MR imaging[J/OL]. Magn Reson Med Sci, 2022 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/36517010/. DOI: 10.2463/mrms.mp.2022-0051.
[40]
FIDOCK B, BARKER N, BALASUBRAMANIAN N, et al. A systematic review of 4D-flow MRI derived mitral regurgitation quantification methods[J/OL]. Front Cardiovasc Med, 2019, 6: 103 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/31428619/. DOI: 10.3389/fcvm.2019.00103.
[41]
WU Z N, NIE C R, ZHU C S, et al. Mitral annular calcification in obstructive hypertrophic cardiomyopathy: incidence, risk factors, and prognostic value after myectomy[J/OL]. Int J Cardiol, 2023, 391: 131266 [2023-05-28]. https://pubmed.ncbi.nlm.nih.gov/37574021/. DOI: 10.1016/j.ijcard.2023.131266.
[42]
GUO Y, ZHANG R S. Expert consensus for standard assessment by echocardiography in Chinese adults with valvular heart disease[J]. Chin Circ J, 2021, 36(2): 109-125. DOI: 10.3969/j.issn.1000-3614.2021.02.002.
[43]
LOPEZ-MATTEI J C, IBRAHIM H, SHAIKH K A, et al. Comparative assessment of mitral regurgitation severity by transthoracic echocardiography and cardiac magnetic resonance using an integrative and quantitative approach[J]. Am J Cardiol, 2016, 117(2): 264-270. DOI: 10.1016/j.amjcard.2015.10.045.
[44]
URETSKY S, GILLAM L, LANG R, et al. Discordance between echocardiography and MRI in the assessment of mitral regurgitation severity: a prospective multicenter trial[J]. J Am Coll Cardiol, 2015, 65(11): 1078-1088. DOI: 10.1016/j.jacc.2014.12.047.
[45]
RIBEYROLLES S, MONIN J L, ROHNEAN A, et al. Grading mitral regurgitation using 4D flow CMR: comparison to transthoracic echocardiography[J]. Echocardiography, 2022, 39(6): 783-793. DOI: 10.1111/echo.15364.
[46]
LEE J, GUPTA A N, MA L E, et al. Valvular regurgitation flow jet assessment using in vitro 4D flow MRI: implication for mitral regurgitation[J]. Magn Reson Med, 2022, 87(4): 1923-1937. DOI: 10.1002/mrm.29082.
[47]
ASHKIR Z, JOHNSON S, LEWANDOWSKI A J, et al. Novel insights into diminished cardiac reserve in non-obstructive hypertrophic cardiomyopathy from four-dimensional flow cardiac magnetic resonance component analysis[J]. Eur Heart J Cardiovasc Imaging, 2023, 24(9): 1192-1200. DOI: 10.1093/ehjci/jead074.
[48]
LAPENNA E, NISI T, CARINO D, et al. Hypertrophic cardiomyopathy with moderate septal thickness and mitral regurgitation: long-term surgical results[J]. Eur J Cardiothorac Surg, 2021, 60(2): 244-251. DOI: 10.1093/ejcts/ezab097.
[49]
SUN D K, SCHAFF H V, VAN HOUTEN H K, et al. Longitudinal cost of septal myectomy versus alcohol septal ablation for hypertrophic cardiomyopathy[J]. Mayo Clin Proc, 2022, 97(9): 1656-1663. DOI: 10.1016/j.mayocp.2022.02.014.
[50]
LEHMAN S J, CROCINI C, LEINWAND L A. Targeting the sarcomere in inherited cardiomyopathies[J]. Nat Rev Cardiol, 2022, 19(6): 353-363. DOI: 10.1038/s41569-022-00682-0.

PREV Advances in the application of cardiac MRI in diagnosis of Fabry disease
NEXT Research progress on MRI radiomics in the progression, recurrence and prognosis prediction of hepatocellular carcinoma
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn